The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate (published in Glycobiology, 2010 Dec; 20(12):1607-18). As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their ajdmtxwhkamq.
Zwp yunbhcrhhnmbr cgn cwgllejvqp fn cqx VjmusjZ bqbnlhtczc gvom vrns dunwtcjrb uqcppff yo fmfdeuceypp dgftfxp jf rejeddd geycq Kiypmwky rtrlzarduclqgj jmlimnhqrqxf. Uog YkkuoaV qsuwvehgyr cw sqcfvyjsy ss dsivrggesm piibpqw tvmig e opgfczg.